VALSARTAN TO ATTENUATE RENAL DAMAGE IN UNILATERAL URETERAL OBSTRUCTION
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This experimental study aims to observe the effect of valsartan to attenuate renal damage in unilateral ureteral obstruction. Material & method: Experimental study was performed using 30 wistar rats with unilateral ureteral obstruction achieved by ligation of the left ureter. Rats were divided into two groups, no treatment group and valsartan group. At the 14th day, evaluation was performed to compare interstitial fibrosis, hydropic degeneration, and tubular atrophy between the two groups using haematoxylin-eosin staining. Only rats surviving until at least the 7th day are included in the study. Results: From thirteen wistar rats in no treatment group, there were two with moderate interstitial fibrosis and eleven with mild interstitial fibrosis while all rats in valsartan group had mild interstitial fibrosis (p > 0.05). There is no significant difference on hydropic degeneration between no treatment and valsartan group (31.46 vs 33.67; p > 0.05). There is also no significant difference in tubular atrophy between the two groups (61.78 vs 62.07; p > 0.05). Conclusion: Valsartan therapy in antihypertensive dosage has no significant effect in to attenuate interstitial fibrosis, hydropic degeneration, and tubular atrophy in unilateral ureteral obstruction in wistar rats. Keywords: Unilateral ureteral obstruction, valsartan, interstitial fibrosis.
##plugins.themes.bootstrap3.article.details##
Singh I, Strandhoy J, Assimos D. Patophysiology of urinary tract obstruction, in Campbell-Walsh Urology. Philadelphia: Elsevier Saunders; 2012. p. 1087-121.
Zecher M, Guichard C, Velasquez M, Figuerosa G, Rodrigo R. Implications of oxidative stress in the pathophysiology. Urology Research. 2009; 37: 19-26.
Chevalier R. Molecular and cellular pathophysiology. Pediatric Nephrology. 1999; 13: 612-9.
Pat B, Tang T, Kong C, Diannewatters D, Johnson GG. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: Modulation by antioxidants. Kidney International. 2005; 67: 931-43.
Grande M, Pérez-Barriocanal F, López-Novoa J. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. Journal of Inflammation. 2010; 7: 1-14.
Klahr S, Morissey J. Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Kidney International. 2002; 62: S23-S26.
Maillard M, Würzner G, Nussberger J, Centeno C, Burnier B, Brunner H. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clinical Pharmacology and Therapeutics. 2002; 71: 68-76.
Siddiqui N, Husain A, Chaudhry L, Alam M, Mitrra MBO. Pharmacological and pharmaceutical profile of valsartan: A Review. Journal of Pharmaceutical Science. 2011; 1(4): 12-9.
Saydam M, Takka S. Bioavailability File: Valsartan. Journal of Pharmacological Science. 2007; 32: 185-96.
Criscione L, de Gasparo M, Biihlmayer P, Whitebread S, Ramjoue H, Wood J. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. British Journal of Pharmacology. 1993; 110: 761-71.
Banff C. Draft guideline for scoring and reporting interstisial fibrosis. Working group on fibrosis; 2009.
Esteban V, Lorenzo O, Rupérez M, Suzuki Y, Mezzano S, Blanco J, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. Journal of American Society of Nephrology. 2004; 15: 1514-29.
Lubis M A. Pengaruh pemberian valsartan dan kurkumin pada obstruksi ureter unilateral. Departemen Bedah Fakultas Kedokteran Universitas Andalas: Padang; 2012.
Hvistendahl J, Pedersen T, Djurhuus J, Pedersen E, Frøkiær J. Losartan attenuates renal vasoconstriction in response to acute unilateral ureteral occlusion in pigs. Urology Research. 2002; 30: 169-77.
Manucha W, Oliveros L, Carrizo L, Seltzer A, Valles P. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney International. 2004; 65: 2091-107.
Liu B, Xia H, Wu J, Zhang X, Liu D, Gong Y. Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction. Acta Pharmacol Sin. 2007; 11(28): 1810-8.
Brenner B, Cooper M, Zeeuw D, Keane W. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine. 2001; 345: 861-9.
Lewis E, collegues. Renoprotective effect if the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine. 2001; 345: 851-60.
Wu W, Chang C, Chiu Y, Ku C, Wen M, Shu K, et al. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. American Journal of Physiology Renal Physiology. 2010; 299: F929-F941.